Cargando…
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
BACKGROUND: Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events. Often, these types of safety data are collected as two discrete data sets, where adverse events that also meet the criteria for seriousne...
Autores principales: | James, Elizabeth C., Dunn, David, Cook, Adrian D., Clamp, Andrew R., Sydes, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495966/ https://www.ncbi.nlm.nih.gov/pubmed/32943106 http://dx.doi.org/10.1186/s13063-020-04718-z |
Ejemplares similares
-
Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria
por: Naing, Cho, et al.
Publicado: (2012) -
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018) -
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks
por: Stegherr, Regina, et al.
Publicado: (2021) -
Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021) -
Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)